Inactive Instrument

Highlights Onconova Therapeutics Inc Nasdaq

Equities

US68232V3069

Highlights

Unlock all the news: Be the first to know and act before the market!

Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	May. 07	CI
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics	Apr. 02	MT
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.	Apr. 01	CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma	Dec. 12	CI
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s	Dec. 08	CI
Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Posts Q3 Revenue $57,000	Nov. 14	MT
Onconova Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Reports Q2 Revenue $57,000, vs. Street Est of $0.07M	23-08-10	MT
Onconova Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma	23-06-14	CI
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade	23-05-25	CI
Onconova Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer	23-05-11	CI
Onconova Therapeutics, Inc. and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib	23-03-23	CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-16	CI
Onconova Therapeutics, Inc. Presents Preclinical Data Characterizing Rigosertibâ€™s Mechanisms	23-03-07	CI
Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma	23-02-07	CI
Onconova Therapeutics Discloses Plan for Phase 1/2a Cancer Trial	22-11-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Onconova Therapeutics Inc Nasdaq

Equities

US68232V3069

Highlights

Filters